A weekly round-up of the
latest coverage in psychedelics.
Receive the free weekly digest straight to your inbox every week
By signing up, you agree to our privacy policy. You can unsubscribe at any time.
Explore our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts.
Pα+ Psychedelic Bulletin #183
“The main theme of the companies it wants to build? No tripping.”
Bullish on Chaos: Matt Zorn on How Psychedelics Could Benefit from Trump’s Second Term
After years of challenging the U.S. government over its drug laws and their application, lawyer Matt Zorn is bullish about the potential regulatory openings that an incoming Trump administration might present. Here, he discusses the types of ‘deeper questions’ we might ask about the U.S. system of drug and medicines regulation and how we might begin to reimagine it.
Interview: Inside the FDA’s Psychedelics Journey: Javier Muniz, MD on Breakthroughs, Challenges, and the Future of the Field
Psychedelic Alpha’s Josh Hardman speaks with Javier Muniz, MD, who recently left his post as Associate Director at the FDA’s Division of Psychiatry. In that role, Muniz was at the heart of the agency’s psychedelics learning journey and helped formulate its view on thorny topics in psychedelic drug development like functional unblinding and the role of psychotherapy. This interview is far-reaching and provides a unique look into both the mind of the regulator, but also Muniz’s own views on psychedelics, now that he is unencumbered by his position in the agency.
The memorial will take place on Thursday, December 19, from 5:30-8:00 pm. More info and RSVP.
The trailer for a Netflix documentary which follows NFL star Aaron Rodgers has been released, with the film set to drop on December 17th. It prominently features his use of ayahuasca.
Interviews: Meet the Team Who Challenged the DEA on DOI and DOC
Dr. Alaina M. Jaster profiles the scientists, advocates and lawyers challenging the agency’s proposed scheduling of two phenethylamine psychedelics.
Free subscribers receive a weekly round-up of news on psychedelics, as well as the occasional article.
Receive regular bulletins, articles, interviews with insiders and quick-take analysis of major stories and developments.
Teams, groups and corporate pricing plans are available, please get in touch via email to learn more.
Front-row access to the psychedelics space: breaking bulletins, in-depth articles, insider interviews and sharp analysis of the moments that matter—from major trial results and funding rounds to policy shifts shaping the future. Plus, full access to our complete archive and Library.
Learn More| Free | ||
|---|---|---|
| Weekly Psychedelic News Feed | ||
| Occasional Articles & Free Resources | ||
| Psychedelic Bulletins (In-Depth Briefings, Multiple per Month) | ||
| Quick-Take Analysis of Major Developments | ||
| In-Depth Articles & Deep Dives | ||
| Exclusive Interviews with Insiders & KOLs | ||
| Quarterly Video Briefings | ||
| Exclusive Tools & Data Resources | ||
| Library of Primers & Explainers | ||
|
Subscribe Now |
||
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
By signing up, you agree to our privacy policy. You can unsubscribe at any time.
Aside from group pricing, we also offer bespoke reports and regular briefings. Get in touch to discuss.